1 |
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024, 74(3): 229⁃263. doi:10.3322/caac.21834
doi: 10.3322/caac.21834
|
2 |
HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022[J]. Natl Cancer Cent, 2024, 4(1): 47⁃53. doi:10.1016/j.jncc.2024.01.006
doi: 10.1016/j.jncc.2024.01.006
|
3 |
LEITER A, VELUSWAMY R R, WISNIVESKY J P. The global burden of lung cancer: Current status and future trends[J]. Nat Rev Clin Oncol, 2023, 20(9): 624⁃639. doi:10.1038/s41571-023-00798-3
doi: 10.1038/s41571-023-00798-3
|
4 |
吴雪杰,陈东来,朱蓉英,等.多发肺结节的基础研究和临床治疗进展[J].中国肺癌杂志,2019,22(3):173-177.
|
5 |
钟华,姚烽,陈群慧,等.肺部多发结节的诊断和治疗[J]. 中华肿瘤杂志,2023,45(6):455-463.
|
6 |
ZHANG Y K, CHAI Z, TAN L, et al. Association of lymph node involvement with the prognosis of pathological T1 invasive non-small cell lung cancer[J]. World J Surg Oncol, 2017, 15(1): 1⁃8. doi:10.1186/s12957-017-1098-3
doi: 10.1186/s12957-017-1098-3
|
7 |
NICHOLSON A G, TSAO M S, BEASLEY M B, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015[J]. Thorac Oncol Off Publ Int Assoc Study Lung Cancer,2022, 17(3): 362⁃387. doi:10.1016/j.jtho.2021.11.003
doi: 10.1016/j.jtho.2021.11.003
|
8 |
LORTET-TIEULENT J, SOERJOMATARAM I, FERLAY J, et al. International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women[J]. Lung Cancer Amst Neth, 2014, 84(1): 13⁃22. doi:10.1016/j.lungcan.2014.01.009
doi: 10.1016/j.lungcan.2014.01.009
|
9 |
中华医学会呼吸病学分会间质性肺疾病学组, 中国医师协会呼吸医师分会间质性肺疾病工作委员会. 中国肺结节病诊断和治疗专家共识[J]. 中华结核和呼吸杂志,2019,42(9): 685-693.
|
10 |
JIANG L, HE J, SHI X, et al. Prognosis of synchronous and metachronous multiple primary lung cancers: Systematic review and meta-analysis[J]. Lung Cancer Amst Neth, 2015, 87(3): 303⁃310. doi:10.1016/j.lungcan.2014.12.013
doi: 10.1016/j.lungcan.2014.12.013
|
11 |
郭海法,毛锋,张辉,等.同时性多原发肺癌的预后及生存相关因素研究[J].中国肺癌杂志,2017,20(1):21-27.
|
12 |
丁小胜,汤传昊,王志杰,等.雌激素在非小细胞肺癌中的研究进展[J].中国肺癌杂志,2017,20(7):499-504.
|
13 |
LIU W, KONDURI S D, BANSAL S, et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function[J]. Biol Chem, 2006, 281(15): 9837⁃9840. doi:10.1074/jbc.c600001200
doi: 10.1074/jbc.c600001200
|
14 |
HYDER S M, NAWAZ Z, CHIAPPETTA C, et al. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor[J]. Cancer Res, 2000, 60(12): 3183⁃3190.
|
15 |
IKEDA K, SHIRAISHI K, YOSHIDA A, et al. Synchronous Multiple Lung Adenocarcinomas: Estrogen Concentration in Peripheral Lung[J]. PloS One, 2016, 11(8): e0160910. doi:10.1371/journal.pone.0160910
doi: 10.1371/journal.pone.0160910
|
16 |
HOFFMAN R M, ATALLAH R P, STRUBLE R D, et al. Lung Cancer Screening with Low-Dose CT: A Meta-Analysis[J]. Gen Intern Med, 2020, 35(10): 3015⁃3025. doi:10.1007/s11606-020-05951-7
doi: 10.1007/s11606-020-05951-7
|
17 |
YATABE Y, BORCZUK A C, POWELL C A. Do all lung adenocarcinomas follow a stepwise progression?[J]. Lung Cancer Amst Neth, 2011, 74(1): 7⁃11. doi:10.1016/j.lungcan.2011.05.021
doi: 10.1016/j.lungcan.2011.05.021
|
18 |
ICHINOSE J, KAWAGUCHI Y, NAKAO M, et al. Utility of Maximum CT Value in Predicting the Invasiveness of Pure Ground-Glass Nodules[J]. Clin Lung Cancer, 2020, 21(3): 281⁃287. doi:10.1016/j.cllc.2020.01.015
doi: 10.1016/j.cllc.2020.01.015
|
19 |
MARTIN B, PAESMANS M, MASCAUX C, et al. Ki-67 expression and patients survival in lung cancer: Systematic review of the literature with meta-analysis[J]. Br J Cancer, 2004, 91(12): 2018⁃2025. doi:10.1038/sj.bjc.6602233
doi: 10.1038/sj.bjc.6602233
|
20 |
JI Y, ZHENG M, YE S, et al. PTEN and Ki67 expression is associated with clinicopathologic features of non-small cell lung cancer[J]. Biomed Res, 2014, 28(6): 462⁃467. doi:10.7555/jbr.27.20130084
doi: 10.7555/jbr.27.20130084
|
21 |
RAMI-PORTA R, ASAMURA H, TRAVIS W D, et al. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J]. CA Cancer J Clin, 2017, 67(2): 138⁃155. doi:10.3322/caac.21390
doi: 10.3322/caac.21390
|
22 |
沈涛,卢珠明. 同时性多原发肺癌淋巴结转移规律的临床研究[J]. 岭南现代临床外科, 2021, 21(5): 561.
|
23 |
LIU W, YANG H S, ZHI F H, et al. Macrophage migration inhibitory factor may contribute to the occurrence of multiple primary lung adenocarcinomas[J]. Clin Transl Med, 2023, 13(10): e1368. doi:10.1002/ctm2.1368
doi: 10.1002/ctm2.1368
|
24 |
SAKURAI T, OKUYAMA Y, KOBAYASHI S, et al. GITR controls intestinal inflammation by suppressing IL-15-dependent NK cell activity[J]. FASEB J Off Publ Fed Am Soc Exp Biol, 2020, 34(11): 14820⁃14831. doi:10.1096/fj.202001675r
doi: 10.1096/fj.202001675r
|
25 |
RONCHETTI S, RICCI E, PETRILLO M G, et al. Glucocorticoid-induced tumour necrosis factor receptor-related protein: A key marker of functional regulatory T cells[J]. Immunol Res, 2015, 2015(1): 171520. doi:10.1155/2015/171520
doi: 10.1155/2015/171520
|
26 |
WANG Y, CHEN D, LIU Y, et al. Multidirectional characterization of cellular composition and spatial architecture in human multiple primary lung cancers[J]. Cell Death Dis, 2023, 14(7): 462. doi:10.1038/s41419-023-05992-w
doi: 10.1038/s41419-023-05992-w
|
27 |
WANG Y, HUANG Z, LI B, et al. Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer[J]. CANCER Immunol Immunother, 2024, 73(6): 111. doi:10.1007/s00262-024-03703-8
doi: 10.1007/s00262-024-03703-8
|
28 |
中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2023版)[J]. 中华医学杂志, 2023, 103(27): 2037-2074.
|
29 |
WATANABE T, TANAHASHI M, SUZUKI E, et al. Surgical treatment for synchronous multiple primary lung cancer: Is it possible to achieve both curability and preservation of the pulmonary function?[J]. Thorac Cancer, 2021, 12(22): 2996⁃3004. doi:10.1111/1759-7714.14164
doi: 10.1111/1759-7714.14164
|
30 |
ISHIKAWA Y, NAKAYAMA H, ITO H, et al. Surgical treatment for synchronous primary lung adenocarcinomas[J]. Ann Thorac Surg, 2014, 98(6): 1983⁃1988. doi:10.1016/j.athoracsur.2014.07.006
doi: 10.1016/j.athoracsur.2014.07.006
|
31 |
彭岳, 王晖, 谢厚耐, 等. 同时性多原发肺腺癌的外科治疗及预后[J]. 中国肺癌杂志, 2017, 20(2): 107⁃113.
|
32 |
姜格宁, 陈昶, 朱余明, 等. 上海市肺科医院磨玻璃结节早期肺腺癌的诊疗共识(第一版)[J]. 中国肺癌杂志,2018, 21(3): 147-159.
|
33 |
中国医药教育协会肺癌医学教育委员会, 中国胸外科肺癌联盟, 中国抗癌协会肿瘤消融治疗专业委员会,等. 多发磨玻璃结节样肺癌多学科诊疗中国专家共识(2024年版)[J]. 中华内科杂志,2024,63(2): 153-169.
|
34 |
SUN C, MEZZADRA R, SCHUMACHER T N. Regulation and Function of the PD-L1 Checkpoint[J]. Immunity, 2018, 48(1): 434⁃452. doi:10.1016/j.immuni.2018.03.014
doi: 10.1016/j.immuni.2018.03.014
|
35 |
SCHOENFELD A J, RIZVI H, BANDLAMUDI C, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas[J]. Ann Oncol Off J Eur Soc Med Oncol, 2020, 31(5): 599⁃608. doi:10.1016/j.annonc.2020.01.065
doi: 10.1016/j.annonc.2020.01.065
|
36 |
HU C, ZHAO L, LIU W, et al. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers[J]. Immunother Cancer, 2021, 9(12): e003773. doi:10.1136/jitc-2021-003773
doi: 10.1136/jitc-2021-003773
|
37 |
SODA M, TAKADA S, TAKEUCHI K, et al. A mouse model for EML4-ALK-positive lung cancer[J]. Proc Natl Acad Sci U S A, 2008, 105(50): 19893⁃19897. doi:10.1073/pnas.0805381105
doi: 10.1073/pnas.0805381105
|
38 |
PAN Y, ZHANG Y, LI Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features[J]. Lung Cancer Amst Neth, 2014, 84(2): 121⁃126. doi:10.1016/j.lungcan.2014.02.007
doi: 10.1016/j.lungcan.2014.02.007
|
39 |
FAN L, FENG Y, WAN H, et al. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: A systematic review and meta-analysis[J]. PloS One, 2014, 9(6); e100866. doi:10.1371/journal.pone.0100866
doi: 10.1371/journal.pone.0100866
|
40 |
CHIA P L, MITCHELL P, DOBROVIC A, et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors[J]. Clin Epidemiol, 2014, 6(1): 423⁃432.
|